[go: up one dir, main page]

Holdsworth et al., 1982 - Google Patents

An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.

Holdsworth et al., 1982

View PDF
Document ID
3297279772533627155
Author
Holdsworth G
Stocks J
Dodson P
Galton D
et al.
Publication year
Publication venue
The Journal of clinical investigation

External Links

Snippet

An abnormal triglyceride-rich lipoprotein has been isolated from some patients with chronic renal failure or severe hypertriglyceridemia. The abnormal lipoprotein was characterized by an increased content of apolipoprotein (apo) C-III-2 (57.5% of total apo C-III peptides …
Continue reading at www.jci.org (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Similar Documents

Publication Publication Date Title
Holdsworth et al. An abnormal triglyceride-rich lipoprotein containing excess sialylated apolipoprotein C-III.
Weisgraber et al. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1.
Baggio et al. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.
Wang et al. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
Castro et al. Effects of postprandial lipemia on plasma cholesterol metabolism.
Malloy et al. Normotriglyceridemic abetalipoproteinemia. absence of the B-100 apolipoprotein.
Beisiegel et al. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein.
Mahley et al. Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B, E and apo-E receptors.
Kissebah et al. Plasma low density lipoprotein transport kinetics in noninsulin-dependent diabetes mellitus.
Eto et al. Apolipoprotein E polymorphism and hyperlipemia in type II diabetics
Schaefer et al. Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis
Millar The sialylation of plasma lipoproteins
McLeod et al. Plasma lipoproteins and lecithin: cholesterol acyltransferase distribution in patients on dialysis
Fless et al. Serum low density lipoproteins with mitogenic effect on cultured aortic smooth muscle cells
Saku et al. Apolipoprotein AI and AII metabolism in patients with primary high-density lipoprotein deficiency associated with familial hypertriglyceridemia
Meng et al. Presence of two forms of apolipoprotein B in patients with dyslipoproteinemia.
Kashyap et al. Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome
Hoeg et al. Characterization of hepatic low density lipoprotein binding and cholesterol metabolism in normal and homozygous familial hypercholesterolemic subjects.
Stocks et al. Hypertriglyceridaemia associated with an abnormal triglyceride-rich lipoprotein carrying excess apolipoprotein C-III-2
Kashyap et al. Abnormal preponderance of sialylated apolipoprotein CIII in triglyceride rich lipoproteins in type V hyperlipoproteinemia
Shore et al. Abnormal high density lipoproteins in cerebrotendinous xanthomatosis.
Taskinen et al. In vitro catabolism of human plasma very low density lipoproteins: Effects of VLDL concentration on the interconversion of high density lipoprotein subfractions
Kobayashi et al. Lipoprotein lipase with a defect in lipid interface recognition in a case with type I hyperlipidaemia
Berry et al. Role of the liver in the degradation of very low density lipoproteins: a study of lipolysis by heparin releasable liver lipase and uptake during isolated rat liver perfusion
Markel et al. Increased plasma triglycerides, cholesterol and apolipoprotein E during prolonged fasting in normal subjects